Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 8/20 | 0.58 |
| ▸ | THRA | P10827 | 7/20 | 0.58 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 3/20 | 0.49 |
| ▸ | KDM1A | O60341 | 2/20 | 0.49 |
| ▸ | MAOA | P21397 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | DHODH | Q02127 | 2/20 | 0.46 |
| ▸ | ESR1 | P03372 | 1/20 | 0.46 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.46 |
| ▸ | PGR | P06401 | 1/20 | 0.46 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.46 |
| ▸ | AR | P10275 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30674665 | 0.91 | KDM1A (0.56) | THRBTHRAMAPTGAAHPGD | |
| SCHEMBL3606076 | 0.91 | KDM1A (0.56) | THRBTHRAMAPTGAAHPGD | |
| SCHEMBL9321924 | 0.86 | THRB (0.46) | THRBTHRAMAPTGAAHPGD | |
| SCHEMBL28598401 | 0.85 | GAA (0.65) | THRBTHRAMAPTGAAHPGD | |
| SCHEMBL20659239 | 0.81 | KDM1A (0.49) | THRBTHRAMAPTGAAMAOB | |
| SCHEMBL1502370 | 0.81 | THRB (0.58) | THRBTHRAMAPTGAAHPGD | |
| SCHEMBL8806810 | 0.81 | THRB (0.58) | THRBTHRAMAPTGAAHPGD | |
| SCHEMBL23883871 | 0.81 | KDM1A (0.49) | THRBTHRAMAPTMAOBKDM1A | |
| SCHEMBL30335518 | 0.81 | KDM1A (0.49) | THRBTHRAMAPTMAOBKDM1A | |
| SCHEMBL15729561 | 0.81 | MAPT (0.57) | THRBTHRAMAPTGAAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8101619-B2 | Phenylpiperazine derivatives with a combination of partial dopamine-D2 receptor agonism and serotonin reuptake inhibition | SOLVAY PHARMACEUTICALS B.V. (NL) | 2012-01-24 | — | — | US | disclosed |
| US-8101619-B2 | Phenylpiperazine derivatives with a combination of partial dopamine-D2 receptor agonism and serotonin reuptake inhibition | SOLVAY PHARMACEUTICALS B.V. (NL) | 2012-01-24 | — | — | US | disclosed |
| US-20070142397-A2 | PHENYPIPERAZINE DERIVATIVES WITH A COMBINATION OF PARTIAL DOPAMINE-D2 RECEPTOR AGONISM AND SEROTONIN REUPTAKE INHIBITION | SOLVAY PHARMECEUTICALS B.V. (NL) | 2007-06-21 | — | — | US | disclosed |
| US-20070142397-A2 | PHENYPIPERAZINE DERIVATIVES WITH A COMBINATION OF PARTIAL DOPAMINE-D2 RECEPTOR AGONISM AND SEROTONIN REUPTAKE INHIBITION | SOLVAY PHARMECEUTICALS B.V. (NL) | 2007-06-21 | — | — | US | disclosed |
| US-20070072870-A2 | PHENYLPIPERAZINE DERIVATIVES WITH A COMBINATION OF PARTIAL DOPAMINE-D2 RECEPTOR AGONISM AND SEROTONIN REUPTAKE INHIBITION | SOLVAY PHARMECEUTICALS B.V. (NL) | 2007-03-29 | — | — | US | disclosed |
| US-20070072870-A2 | PHENYLPIPERAZINE DERIVATIVES WITH A COMBINATION OF PARTIAL DOPAMINE-D2 RECEPTOR AGONISM AND SEROTONIN REUPTAKE INHIBITION | SOLVAY PHARMECEUTICALS B.V. (NL) | 2007-03-29 | — | — | US | disclosed |
| WO-2006061379-A1 | PHENYLPIPERAZINE DERIVATIVES WITH A COMBINATION OF PARTIAL DOPAMINE-D2 RECEPTOR AGONISM AND SEROTONIN REUPTAKE INHIBITION | SOLVAY PHARMACEUTICALS B.V. (NL) | 2006-06-15 | — | — | WO | disclosed |
| US-20060122189-A1 | Phenylpiperazine derivatives with a combination of partial dopamine-D2 receptor agonism and serotonin reuptake inhibition | SOLVAY PHARMACEUTICALS B.V. | 2006-06-08 | — | — | US | disclosed |
| US-20060122189-A1 | Phenylpiperazine derivatives with a combination of partial dopamine-D2 receptor agonism and serotonin reuptake inhibition | SOLVAY PHARMACEUTICALS B.V. | 2006-06-08 | — | — | US | disclosed |
| EP-0368429-B1 | Fluor-substituted benzene derivatives | SCHERING AG (DE) | 1994-02-09 | — | — | EP | disclosed |
| EP-0579261-A1 | Fluorosubstituted benzene derivatives | SCHERING AKTIENGESELLSCHAFT (DE) | 1994-01-19 | — | — | EP | disclosed |
| US-5130119-A | Sulfonamide or hydroxy fluorine substituted benzene for medical diagnosis | SCHERING AKTIENGESELLSCHAFT (DE) | 1992-07-14 | — | — | US | disclosed |
| EP-0368429-A2 | Fluor-substituted benzene derivatives | SCHERING AKTIENGESELLSCHAFT (DE) | 1990-05-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072870-A2 | PHENYLPIPERAZINE DERIVATIVES WITH A COMBINATION OF PARTIAL DOPAMINE-D2 RECEPTOR AGONISM AND SEROTONIN REUPTAKE INHIBITION | HTR2C, HTR2A, HTR5A | THRB 191/4885THRA 286/4885MAPT 755/4885 |
| US-20060122189-A1 | Phenylpiperazine derivatives with a combination of partial dopamine-D2 receptor agonism and serotonin reuptake inhibition | HTR2C, HTR2A, HTR5A | THRB 191/4885THRA 286/4885MAPT 755/4885 |
| US-20070142397-A2 | PHENYPIPERAZINE DERIVATIVES WITH A COMBINATION OF PARTIAL DOPAMINE-D2 RECEPTOR AGONISM AND SEROTONIN REUPTAKE INHIBITION | HTR2C, HTR2A, HTR5A | THRB 254/4885THRA 394/4885MAPT 2881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.